Scholarlink

<p>Currently, there is limited evidence supporting ensartinib’s efficacy as a neoadjuvant treatment for locally advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). This case study describes a 65-year-old female who presented with an incidental pulmonary lesion and was diagnosed with unresectable locally advanced stage IIIB (cT3N2M0) ALK-positive NSCLC. After multidisciplinary evaluation, she underwent 12 weeks of neoadjuvant ensartinib therapy (225&#xa0;mg/day, later reduced to 175&#xa0;mg/day), achieving a 78.4% reduction in tumor volume and reassessment as resectable. Subsequently, video-assisted thoracoscopic surgery (VATS) comprising a right upper lobectomy and systematic lymph node dissection resulted in R0 resection. Postoperative pathological analysis confirmed pathological complete response (pCR). During an fifteen-month follow-up, no recurrence of the disease was detected.</p><p>These results indicate that ensartinib may provide potential benefit for patients with locally advanced ALK-positive NSCLC by optimizing surgical feasibility and survival outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ensartinib targeted conversion surgery for ALK-positive unresectable locally advanced non-small cell lung cancer: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Sijin Huang,
  • Chuan Yuan,
  • Yanheng Wang,
  • Binbin Chen,
  • Wenfang Tang,
  • Haiming Jiang,
  • Wenhao Li,
  • Yi Liang,
  • Weizhao Huang

摘要

Currently, there is limited evidence supporting ensartinib’s efficacy as a neoadjuvant treatment for locally advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). This case study describes a 65-year-old female who presented with an incidental pulmonary lesion and was diagnosed with unresectable locally advanced stage IIIB (cT3N2M0) ALK-positive NSCLC. After multidisciplinary evaluation, she underwent 12 weeks of neoadjuvant ensartinib therapy (225 mg/day, later reduced to 175 mg/day), achieving a 78.4% reduction in tumor volume and reassessment as resectable. Subsequently, video-assisted thoracoscopic surgery (VATS) comprising a right upper lobectomy and systematic lymph node dissection resulted in R0 resection. Postoperative pathological analysis confirmed pathological complete response (pCR). During an fifteen-month follow-up, no recurrence of the disease was detected.

These results indicate that ensartinib may provide potential benefit for patients with locally advanced ALK-positive NSCLC by optimizing surgical feasibility and survival outcomes.